Trial intelligence / Profile preview

Probiotic Lozenges (Inersan) in Chronic Periodontitis

NCT02121665Phase 3Completed

Sponsor
CD Pharma Group
Start
Jul 2014
Primary completion
Jan 2016
Modality
Yeast Strains, Defined Consortia, Bacterial Strains
Countries
1
01

Overview

A Phase 3 trial of lactobacillus brevis cd2 in chronic periodontitis, sponsored by CD Pharma Group. Started Jul 2014; status: completed.

02

Drugs

lactobacillus brevis cd2
03

Conditions

chronic periodontitis

Beyond the preview

Go deeper on NCT02121665.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02121665.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call